Trial Profile

A Phase Ib Study of the Safety, Pharmacokinetic of Lisaftoclax (APG-2575) Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed/Refractory AML

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Lisaftoclax (Primary) ; Olverembatinib (Primary) ; Omacetaxine mepesuccinate (Primary)
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloid leukaemia
Focus Adverse reactions
Sponsors Ascentage Pharma

Most Recent Events

26 Sep 2025 Planned number of patients changed from 284 to 458.
26 Sep 2025 Planned End Date changed from 1 Aug 2026 to 1 Sep 2029.
26 Sep 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Sep 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com